Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 1
1(25.0%)
Phase 2
1(25.0%)
4Total
N/A(2)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04922476Not ApplicableCompleted

Effect of 35624® Alflorex® in Functional Gastrointestinal Disorders (FGIDs) in Children.

Role: lead

NCT04925440Not ApplicableCompleted

The Effects of Bifidobacterium Longum 1714® in a Population With Low Mood

Role: lead

NCT04167475Phase 2Completed

Effect of B. Longum 1714™ on Sleep Quality

Role: lead

NCT04422327Phase 1Completed

The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome

Role: lead

All 4 trials loaded